ELIZABETH E REED
CIK 1283303 · Chief Legal Officer and GC · last filed 2026-05-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.91M
Companies
4
Total Filings
82
Lifetime Open-Market Net
-$6.93M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVTX | Chief Legal Officer and GC | 105,211 | $65.71 | $6.91M | -$6.42M | 32 | 2026-05-06 |
| Travere Therapeutics, Inc. (RTRX) Delisted | SVP, GC & Corporate Secretary | 25,431 | — | — | -$510.1K | 19 | 2020-11-17 |
| Eiger BioPharmaceuticals, Inc. (CLDN) Delisted | VP, General Counsel | 11 | — | — | $0 | 1 | 2015-01-05 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | SVP, Legal Affairs and GC | — | — | — | $0 | 7 | 2011-01-24 |
Recent Filings · Page 8 of 9
82 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-05-14 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +7,000 | $0 | EDGAR |
| 2018-02-12 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +1,769 | $0 | EDGAR |
| 2018-01-08 | Travere Therapeutics, Inc. (RTRX) Delisted | Sell (S) | −942 | -$22.6K | EDGAR |
| 2017-01-06 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
| 2015-01-05 | Eiger BioPharmaceuticals, Inc. (CLDN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-01-24 | ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-12-15 | ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-12-07 | ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-08-20 | ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-12-12 | ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.